OpenEvidence key facts
as of Oct 2026- Developer of an AI-powered information platform designed to organize medical knowledge and make it useful, accessible, and understandable.
- OpenEvidence is valued at approximately $15.0B as of Oct 2026, set at its Series E, Sep 2026; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $795.4M across 11 recorded rounds; the latest was Series E ($250.0M) in Sep 2026.
- Notable investors include Andreessen Horowitz, Byers Capital, Sequoia Capital, GV, Coatue Management — 45 tracked in total.
- PrivateMarketView tracks 6 recorded secondary trades in OpenEvidence shares.
- 1 investment vehicle was formed to buy OpenEvidence shares in the last 12 months, reporting $5.8M sold to 79 investors, per SEC Form D filings.
- Status: Privately Held (backing).
Valued at $15.0B at its Series E, Sep 2026. Nothing has traded since.
Membership and data by Private Market View
- ·Post-money valuations for 9 rounds
- ·The complete investor list: 45 names
- ·Watch OpenEvidence: the Monday email on marks, rounds and moves
OpenEvidence secondary trades
6 on record · Mar 2026 – May 20266 trades between Mar 2026 and May 2026. Exact dates, prices and structures are available to Pro members.
Membership and data by Private Market View
OpenEvidence funding rounds
11 roundsVehicles formed to buy OpenEvidence shares
secondary demand · SEC Form D filingsIn the last 12 months, 1 investment vehicle were formed to buy OpenEvidence shares, reporting $5.8M sold to 79 investors. Most recent filing Apr 2026.
Membership and data by Private Market View
OpenEvidence leadership
- Daniel Nadler Ph.DCo-Founder & Chief Executive Officer
- Zachary Ziegler Ph.DCo-Founder & Chief Technology Officer
- Andrew StarkChief Revenue Officer
Who backs OpenEvidence
45+Membership and data by Private Market View
OpenEvidence valuation
OpenEvidence was valued at $15 billion at its Series E in Sep 2026. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
Recent activity
In the last 90 days, OpenEvidence's record added 1 funding round.
How much has OpenEvidence raised?
OpenEvidence has raised $795 million across 11 recorded rounds since 2017. The largest was a $75 million Series A in Feb 2025; the most recent was a $250 million Series E in Sep 2026. 9 of the rounds disclosed a post-money valuation.
OpenEvidence secondary market activity
6 secondary trades in OpenEvidence shares are on record, between Mar 2026 and May 2026. The busiest recent months were Apr 2026 (3 prints). Exact dates, prices and structures are available to Pro members.
Institutional holders and vehicles
In the last 12 months, 1 investment vehicle was formed to buy OpenEvidence shares, reporting $5.8 million sold to 79 investors, per SEC Form D filings (most recent Apr 2026).
OpenEvidence investors
45 investors are on record for OpenEvidence, led by Andreessen Horowitz and Byers Capital. By type, the record holds 22 venture capital firms and 3 family offices. 2 of them led at least one round. The Series E in Sep 2026 drew 2 investors.
Who runs OpenEvidence
6 people are listed on the OpenEvidence team: 3 executives and 3 board members, including Daniel Nadler Ph.D (Co-Founder) and Zachary Ziegler Ph.D (Co-Founder). 6 of them have a verified direct contact on file.
About OpenEvidence
Developer of an AI-powered information platform designed to organize medical knowledge and make it useful, accessible, and understandable. The company's platform offers a curated database of journal content, advanced medical AI search, and patient documentation tools to make more evidence-based decisions and improve patient outcomes, enabling healthcare professionals to access relevant research and promote care decision-making.
- Sector
- Healthcare
- HQ
- Miami, FL, United States
- Founded
- 2017
- Employees
- 36
- Website
- openevidence.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.